In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Medical Device

Deals in Depth: June/July 2009

Executive Summary

J&J made news in July by forming a JV with Elan that will develop the latter's Alzheimer's program--including the highly touted Phase III candidate bapineuzumab--in a deal valued at $1.5bn; BMS acquired antibody technologies in its $2bn takeover of Medarex; and financing for medical device firms grew in June and July with most of the money coming from late-stage venture rounds, while biopharma fundraising went down in June but rebounded the following month thanks to a strong showing from follow-on public offerings.
Table

View full table

Advertisement

Topics

Advertisement
Tags:
BioPharmaceutical Medical Device
UsernamePublicRestriction

Register

IV003355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By